Citation: Leukemia & Lymphoma. :1-8, 2020 Jul 11.Journal: Leukemia & lymphoma.Published: ; 2020ISSN: 1026-8022.Full author list: Desai SH; Al-Shbool G; Desale S; Veis J; Malkovska V.UI/PMID: 32654590.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Washington Hospital Center | MedStar Heart & Vascular Institute | Washington Cancer InstituteDepartment(s): Medicine/Internal Medicine | Medicine/NephrologyActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1080/10428194.2020.1786555 (Click here)ORCID: Desai, Sanjal H https://orcid.org/0000-0002-7892-2625 (Click here)Abbreviated citation: Leuk Lymphoma. :1-8, 2020 Jul 11.Abstract: With improving lymphoma survival, late effects of therapy have emerged. Here, we describe pattern of long-term chronic kidney disease (CKD) in lymphoma survivors. Demographics, comorbidities, lymphoma histology, treatment, and outcome were recorded. Glomerular filtration rate (GFR) was recorded at diagnosis, 1, 2, 5, and 10 years. Rate of GFR decline with time and CKD-free survival were recorded. In 397 patients, median age was 55.3 (18-88), 54% were male, 60% were African Americans, 42% had hypertension (HTN), 15% had DM, 13% had hyperuricemia, 86% received chemotherapy, and 14% had baseline CKD. Total 125 (31%) patients developed CKD in 10 years after lymphoma diagnosis. Probability of CKD development increased significantly with time (23% at 1 year to 41% at 10 years). Rate of GFR decline was 4.6 mL/min/per year. Age, HTN, hyperuricemia, and DM (in young patients) predicted risk of CKD. Thus, lymphoma survivors are at substantial long-term risk of CKD development.